-
-
-
-
-
-
-
BofA Securities Starts Alto Neuroscience (ANRO) at Buy
-
-
-
-
-
-
-
Chardan Capital Markets Assumes Alto Neuroscience (ANRO) at Buy
-
-
-
-
-
-
-
Alto Neuroscience plans Phase 3 depression drug study by early 2027
-
-
-
-
-
-
-
William Blair Reiterates Outperform Rating on Alto Neuroscience (ANRO)
-
-
-
-
-
-
-
Alto Neuroscience (ANRO) Announces U.S. Patent Granted Covering ALTO-300
-
-
-
-
-
-
-
After-hours movers: McDonald's, Starbucks, Seagate, Alto Neuroscience and more
-
-
-
-
-
-
-
Alto Neuroscience (ANRO) Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
-
456,994 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

